| Autor: |
Pratelli A; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy., Capozza P; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy., Minesso S; Department of Veterinary Science, University of Parma, 43126 Parma, Italy., Lucente MS; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy., Pellegrini F; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy., Tempesta M; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy., Franceschi V; Department of Veterinary Science, University of Parma, 43126 Parma, Italy., Buonavoglia C; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy., Donofrio G; Department of Veterinary Science, University of Parma, 43126 Parma, Italy. |
| Abstrakt: |
Bovine coronavirus (BCoV) is distributed globally and mainly causes different clinical manifestations: enteric diarrhea in calves, winter dysentery in adults, and respiratory symptoms in cattle of all ages. Low mortality and high morbidity are the hallmarks of BCoV infection, usually associated with substantial economic losses for the livestock industry. Vaccination, combined with the implementation of biosecurity measures, is the key strategy for the prevention of infections. This pilot study evaluates the immunogenicity of a recombinant vaccine containing two BCoV antigens (S and M) in sheep, compared to vaccines containing only the M or S protein. Three groups of sheep were inoculated intramuscularly at day 0 and day 21 with recombinant adenoviruses expressing BCoV S protein (AdV-BCoV-S), BCoV M protein (AdV-BCoV-M), or both proteins (AdV-BCoV-S + M). Serum antibodies were evaluated using immunofluorescence (IF) and serum neutralization (SN) tests. Moderate seroconversion was observed by day 21, but serum antibodies detected via SN increased from 1:27.5 (day 21) to 1:90 (day 28) in sheep inoculated with the recombinant AdV expressing both the S- and M-BCoV proteins. Based on the SN results, a repeated-measures ANOVA test indicated a more significant difference in immune response between the three groups (F = 20.47; p < 0.001). The experimental investigation produced satisfactory results, highlighting that the S + M recombinant vaccine was immunogenic, stimulating a valid immune response. Despite some inherent limitations, including a small sample size and the absence of challenge tests, the study demonstrated the efficacy of the immune response induced via the recombinant vaccine containing both S and M proteins compared to that induced via the individual proteins S or M. |
